J&J Recalls Yet More Medicines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

J&J Recalls Yet More Medicines


Pharmaceutical Technology Europe

Johnson & Johnson’s run of quality issues, recalls and other bad news continues with yet another product recall. The company is voluntarily recalling, at the wholesaler level, certain lots of Tylenol, Benadryl, Sudafed PE and Sinutab products distributed in the US, the Caribbean and Brazil. All of the products were manufactured at the company’s McNeil division plant in Fort Washington, which was closed in April 2010 and has been cited by the FDA as having several quality problems.

“The company is initiating the recall as a precautionary measure after an extensive review of past production records found instances where equipment cleaning procedures were insufficient or that cleaning was not adequately documented,” explained a company statement.

The company has also initiated a voluntary recall of certain lots of Rolaids Multi-Symptom Berry Tables in the US to update the labelling. The product labelling currently does not include the language “Does not meet USP”, which is required by regulations.

“McNeil identified the inadequacies as part of a thorough, proactive product quality and process assessment of all McNeil produced products. As previously announced, McNeil has been implementing a Comprehensive Action Plan at its US manufacturing facilities to improve the quality systems at those sites,” said the company statement.

The company submitted its Comprehensive Action Plan to the FDA in July 2010 and undertook a thorough assessment of company historical records. The assessment identified a number of areas for improvement, which are currently being addressed and have led to the latest recalls. McNeil has said that it will continue conducting assessments at other sites that manufacture its products, which may lead to further recalls if any other issues are identified.

In a statement providing an update on the plan, J&J Chairman and CEO Bill Weldon said: “Steps we have taken under the Comprehensive Action Plan constitute an uncompromising and systematic effort to review quality and manufacturing practices at McNeil. They help us assure that moving forward, any of our products in the marketplace live up to the trusted standards and expectations that consumers have for all products coming from a Johnson & Johnson company, anywhere in the world.”

J&J and its subsidiary McNeil Consumer Healthcare have been in industry headlines frequently since 2009 because of product recalls, phantom recalls and related congressional hearings. More information and background can be read in related PharmTech blogs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here